show. your hair looks fantastic. >> thank you. >> thank you. >> yours is okay. >> i can say that. pinterest. maybe it's on my pinterest page available. go buy them. "mad money" starts right now. my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere. i promise to help you find it. "mad money" starts now. i'm cramer. welcome to a special san francisco edition of "mad money." i'm just trying to make you money. my job is not just to entertain but to educate you. call me at 1-800-743-cnbc. sometimes wall street has to

think long-term i. hflong-term. in this business, that mean urz missing numbers or you are dead. that's what i think as we swoop down into the second day of the jp morgan health care conference which is filled with ceos talking about the future of health care. here is what happened. the s&p advanced and the nasdaq lost. why am i willing to focus on the so-called out years? the long-term possibilities for the companies are incredible. incredibly lucrative. as the present is good but not great. at the risk of antagonizing the day traders, let me tell you what i saw today. wasn't to start with a stock that got pummelled today, eli lilly. they announced $56 billion in revenue next year, better than expected. there's one problem here, the

fourth quarter estimates that we finished, they aren't as strong as wall street was hoping. it went from the best of the best to the worst of the worst, finishing at the bottom of the s&p 500 today, which is saying something. because there are 499 other companies that performed better. why am i not pre preturbed? i think thinking zepbound has too many potentials. it will work against hypertension, heart failure, liver disease, joints, dementia and she and heavy drinking. spending $20 billion to build manufacturing, even throw

there are competitors. they are not easy to make. the spending is the secret that will itors at bay. they haven't done a great job launching the drug. it has grown faster than any other large drug. let me ask, do we want the fastest ramp up or the biggest drug of all time? the community balance. i will take the latter any day of the week. did i mention they will have this weight loss drug in pill form, not just injectable? of course, it's not just the box launch that's holding them back. bobby kennedy junior, for health and human services nominee, is known as an anti-vaccine proponent. but you could think of him as a believer in diet and exercise. he is not a fan of the glp-1 drugs. the food industry made diet and

exercise almost impossible. why not let those who can't take the shot? let me give you another negative. the giant head and shoulders pattern, any chart that's worth its salt knows what that spells. it may look ugly for lilly. how about merck? the greatest anti-cancer drug, keytruda. they purchased acceleron. this is a drug that according to merck's ceo has pulled people back from the brink of death. he goes on to explain sick people who use this drug are now -- i will quote -- alive and

may have to go back to work. win some/lose some. gardisil can protect against cervical cancer. women have been using it for years. chinese government approved it for men. merck is having a problem with the chinese distribution. weird situation. the stock is well ensconced. i can't tell you how long it will take to bounce back. does that mean sell? if you are a day trader but not if you are an inventor. how about regeneron? after declining nearly 4% today, it sits at 690. wow. the issue, it's this franchise being challenged by a biosimilar. it's just a generic drug. that's all wall street cares about. doesn't matter if it's working

on 40 compounds. doesn't matter their breakthrough drug is indicated for seven illnesses. this company has never lost its ability to develop new medicine. including the one that saved president-elect trump's life when he caught covid. for now, none of that seems to matter. one day it will. i can't believe abbott labs has a series of lawsuits over its head. i think abbott will win the baby formula cases. what. >> the stock do? it languishes. yesterday, we had the ceo of metronic on. he told a story about the new products that nobody seemed to care about. today, when the stock was one of the best performers in the s&p

500, i remember what he said yesterday. things are darn good. stocks go in and out of style. you know that. i have talked to about that. right now, health care is in a dog house, the likes of which i have never seen. i have to tell you, companies, should they be kept down by rising interest rates? that's why they are so cheap. call me a miser. i like cheap. ask what happens if things get better. what if the future is brighter than the past? if that's the case, and i think it is, you have winners with the drug and medical device plays. glad i could be here to tell you their stories. let's take questions. gregory in california. >> carter: happy new year. i hope you are having a good one so far. >> so far, so good. i love it when you call. that california accent does throw me. >> carter: well, it's been smoke

inhalation. what can i tell you? it changed my voice. we last spoke in early november. it was just before the election when i bought half a position in this stock. $242 if i recall. we talked about the club taking a position in it. it was lisa's birthday weekend. i'm sure you had to celebrate. after the election, this stock rocketed higher. reaching $480. it was a double by mid december before settling down to 380. my question, jim, is should i have trimmed at those ludicrous highs? is now the time to buy the upper half so i can get a full position in a stock that could go, frankly, a lot higher? you know what i'm talking about, tesla. >> it was my wife's birthday. it threw me off my game. gregory, i think your tesla idea is terrific. buy more. ever since we talked last, tesla has become more of a tech stock

and less of a car stock. thank you for the kind words. you are a blast. right now, healthcare is in the dog house. it's really, really depressing. future is brighter than the past. i their you are ink you are get opportunity. abbott labs, merck, cardinalhealth. it's been a jam-packed day. you do not want to miss these interviews. stay with cramer. >> don't miss a second. follow @jimcramer on x. have a question, tweet cramer #madmentions. sent jim an email. give us a call at 1-800-743-cnbc. head to madmoney.cnbc.com.

♪♪ only servicenow connects every corner of your business, putting ai to work for people. pfft ... every corner? every corner, nick. ow! so kate in hr ... hey kate. can focus on people, not process. oh actually, i have a question ... keep up, nick. do you have to be sick to take a sick day? patty in it is using ai agents to deal with the small stuff, so she can work on the big stuff. agents like secret agents? secret agents i control. with your mind? you know ... i played a secret agent once. - we know. - oh gosh ...

i liked it. over here, ai gives tina the info she needs to get the job done. nick, what did we say about touching? no touching. good. ai helps jim solve customer problems before they're problems. for reals? for reals. for reals. servicenow is the only platform that connects every corner of your business, putting ai to work for people. oh, so we all work better, together! my work here is done. excuse me, which way back? uh, follow him.

let's say you're deep in a show or a game or the game. which way back? on a train, at home, at work. okay, maybe not at work. point is at xfinity. we're constantly engineering new ways to get the entertainment you love to you faster and easier than ever. that's what i do. is that love island?

what's next for abbott lob laboratories. they told a very good story at last year's healthcare conference. then it got erailed over baby formula litigation. last fall, they won in court. i am confident it can march higher and invefrtz stors can f on the fundamentals. i sat down with the chairman and ceo of abbott labs. take a look. i want to use this moment to reintroduce abbott. people don't realize what's happened in the last five years, how much bigger and more you are spending on r&d. >> we are one of the most

diversified healthcare companies right now. nutrition, diagnostic, medical device and pharmaceutical in emerging markets. over the last five years, we have grown our revenue $10 billion organically. we have increased our income by $3 billion. we have increased r&d spend by 30%. cap x spend is increased by 60%, investing in digital transformation and manufacturing. we have returned $25 billion to our shareholders. we have been able to invest in the business, grow the big organically and our shareholders have been able to benefit through the return. >> the stock is inexpensive. we have owned it for years, even from your predecessor. many people know you as the people who solve the conundrum about whether they have covid or not. >> yes. that was an interesting period in my first couple of years. a company did incredible work.

that business is now -- as a lot of the covid businesses have gone down. >> we can see who the real abbott is. >> that's now behind us. we have an endemic state. it's $500 million of revenue. those are real earnings that will continue to be there. >> let's talk about the abbott that i think people should know at home. let's talk about libre and your strategy for glucose monitoring. this is one of the most amazing inventions. >> incredible technology. we figured out how to measure glucose. it came in terms of how we manufactured it. at scale. that incredible technology that the team put together allowed us to take a different approach. approach this as a mass market opportunity and price it at a way that allowed for a significant penetration from moving the product from a niche segment to a more broader segment. that's what we are seeing. that's been at the core of ibre

is that scale and leadership allows us to broaden the reimbursement of the system. >> there is a differentiation between one, two and three. three has taken the world by storm. >> correct. it's the nnest sensor. that's important for people with diabetes. we are manufacturing this at scale. we opened a new facility. we were having challenges with demand and supply. >> high quality problem. >> we don't like those problems. now we have invested in supply. that supply is coming online. we will continue to see this very strong growth rate in this platform. >> people have to understand abbott as a health and wellness company. you were the hit with lingo. you have an app one day that will tell us what we are eating, whether it's good or bad. >> lingo is doing great.

last we talked about it, we got approval for it towards the end year. we launched it as a direct to consumer play here in the united states. focusing on four to five cities. >> really tells you how you are doing. >> tells you how you are doing. insight to a personal metabolic coach. translates what you are eating and give u.s.s you insight. what i like is the retention rate and reorder rates are surprising. that means that people not only trying it but they're sticking with it. >> can it be billions? >> this year we will focus on expanding distribution, bring it into retail. then going across the united states. i think over time this could be larger than libre. >> that would be incredible. >> the amount of people -- healthy people that want to stay healthy. there's a lot more people that are in that category than people with diabetes. >> last quarter, litigation problems. the stock goes from 109 to 99.

you were able to come on and we explained that. there's still people who think you got serious litigation risk for a very specialized portion of your -- baby formula. it's backed by the nih, fda and cdc. still there are lawyers suing you. it seems like that may have run its course to some degree. i know that's hard to predict. >> it's hard to predict. i would say i was -- it's a difficult situation for the families to go through this. i would say, i was pleased we won the last case. i was pleased at public statements, the product is a standard of care. there's no causal evidence. let the specialists decide how to feed these very, very fragile -- i think that was a good win. i think we have all got to come together, all the stakeholders and say, this is an important food for these premature babies. let's resolve this.

let's solve this. there are a lot of stakeholders whether regulators -- >> i wanted to go into what you are doing with st. jude, the wires, dual chambers. it's great what you are doing. it's wild card week. next is division playoffs. you are doing concussion work that may resonate throughout the world, particularly are younger people whether we don't foe whether they have concussion or not. >> a rapid blood test that's a ruleout to determine if somebody does not out a concussion. the product we have today is a venus sample. our vision is that this will become available in every single high school in the united states. >> we're not just looking at people's eyes or making subjective judgements. >> an objective blood test to say you do not have a concussion. you can get back in the game. >> how soon can every city and school have this? >> we are working on clinical trials. we are a couple years out.

for the medical environment, physicians can do this test. i'm talking about the end state where a school nurse on a football field -- >> sideline. >> that's a couple years away. >> so horrible. people don't realize. so bad. this is robert ford, chairman and ceo of abbott labs. thank you so much. >> nice to see you. >> coming up, after making breakthroughs in oncology, cramer is sitting down with merck's top brass to learn about how the company is revolutionizing cancer prevention and treatment next.

this has not been a great period for anything healthcare. take merck. it was down almost 9%. is there any reason to think 2025 will be better? they have been putting in effort to deliver more blockbuster drugs. it's running up against patent expirations. the number of phase three drugs in the pipeline has tripled versus three years ago. what's going to move the needle this year? we sat down with rob davis, the chairman, president and ceo of

merck. take a look. when we last talked, you had made an acquisition. people were concerned. now i'm reading it pulled people back from the brink of death. it's that strong a formulation. >> it has been an amazing drug. it has. what we are seeing is -- it's anecdotal. we have had patients on transplant lists who have been taken off almost -- a very short time after starting it. it is having an amazing affect. we need to see it grow, which we are confident it will. it's an important drug. >> i started with that because most people start with keytruda. they don't realize, maybe prostate, bladder, hold and neck. i think when you have one of the greatest drugs of all time, it does tend to blot out others that you are working on. >> i think it's a great point to

raise. keytruda has been transformational in the treatment of cancer. importantly, we are now in a situation where we can literally leverage the strength of keytruda to go well beyond. we now have a much broader pipeline in tissue targeting agents, with antibody drug conjugates. we are broader today. i would no longer think of us as a keytruda company. we are an oncology company. we have other opportunities we can talk about. we are moving into immunology, now into ophthalmology. the breadth and depth of the pipeline we have is the most diversified in the company's recent history, which i'm excited about. >> people don't understand, you are not just targeting the

so-called easy cancers. you are going after cancers that have been worked on for 150 years and no hope. >> one i might highlight that we are excited about, we did a deal in 2024 for a company called harpoon, brought in a t-cell engager. a new approach to think about cancer. when we combine that t-cell engager with the b7h3 conjugate we have, we believe we have an opportunity to go into small cell lung cancer, a significant portion of lung cancer which largely has been untreated. there's been nothing. that's one example where i think now we are at a point to we are able to go after some of the cancers that historically have been very difficult to prosecute. >> it's my job to talk about the stock. i see this stock at 99 with a good-year-a good yield. maybe the problem is gardisil.

robert f. kennedy junior doesn't necessarily believe in vaccines. how big can it be? >> right now, if you look on a global basis, it is an 8ish billion. it peaked at 8.5. we believe we can go and drive towards achieving 11 billion by 2030. because there's still a significant unmet need out there that we have to address. really, a global need. not only continuing to penetrate for females to help with cervical cancer, but for males for hpv related cancers specific to men in addition to helping ensure by having the male population vaccinated, we protect the females. this is an area where we are continuing to invest. i think the science and effectiveness of the drug is proven. it's seen as an anti-cancer vaccine. it's one of the only ones out there. >> let's talk about globally. the chinese have -- they have

not necessarily had what i call a reasonable game plan. that could change. >> if you look where we are in china, we have been really focused to date on the female population. we just got approval for gardasil for males in china in the 9 to 26-year-old category. we are in the middle of launching that. that's 200 million people, 200 million males in the demographic we think we can go after on top of the 120 million females still out there. china is still an opportunity. increasingly, we are looking to how we go beyond china, broadly and frankly beyond gardasil to the breadth of the portfolio we have. >> i do want to talk about glp-1. you are working on things that i know are someone who under promises, possibility of over deliver. you have ideas that are different in terms of making it so it's f it's that big of a drug, there's a lot of room.

>> we have two areas we are focusing on in the glp-1 space. we have in phase development, a glp-1 for mash. this is an injectable peptide that we think is best in class in liver fat reduction. it brings with it weight loss characteristics similar to ozempic. that drug is something we think could be important. while the glp-1s have been important, they have not penetrated the way we think they could. we think we have best in class, which you are referring to is beyond that. we just did a deal to bring in an oral glp-1, small molecule. our belief is, if you can find the right oral small molecule backbone, to drive meaningful outcome improvement beyond just weight loss benefits is -- we are focusing on dealing with

some of the side effects that the current drugs have. nausea, how can you manage those elements? the muscle degradation. it's the next generation of glp-1, we are focused oral, small molecule. that will be out for us in the early 2030s. >> the things you have done are remarkable. most of the time when i see these acquisitions, i get concerned that they can't ever deliver on the numbers. you made the right move. >> thank you very much. >> thank you, rob davis, chairman and ceo of merck. >> great to see you. >> coming up, with regeron shares sliding, cramer is talking to the ceo to find out if what's in the pipeline can revitalize their long-term prospects next.

your shipping manager left to "find themself." leaving you lost. you need to hire. i need indeed. indeed you do. sponsored jobs on indeed are two and a half times faster to first hire. visit indeed.com/hire

>> university of maryland global campus allowed me to write my own story. they want you to succeed, and for me, it was a school of opportunity. i feel like i had a support system behind me within the school. they provided me the opportunity to get my degree, as well as to take the full-time job. umgc put me on a path to be successful by giving me credit for my certifications and transferring my prior course credits. umgc supported me and allowed me to achieve my goals. [ music ]

what the heck just happened to the stock of regeneron pharmaceutical? after spending decades, going higher, it plunged more than 40% from its all-time highs last august. it fell 26 points today or 3.6%. some is because the market has no appreciation for drug stocks. some is because they lost exclusivity for a treatment for macular degeneration. more bad news. they had positive things to say about big drugs. eylea is a huge franchise for these guys. maybe focus on an exciting

pipeline. i spoke with the co -founder an co-chair of regeneron. take a look. i'm thrilled to see you. people may not realize, you were my first guest. your stock was at 5. how would you have done had you bought it and held on to it ? >> it's hard to do the math. up over 100 fold. >> it's good to make money. when i listen to the dialogue, it's about how the first drug -- they should return capital. can we reframe the dialogue? what should people really be thinking about? >> i think you have to understand where drug comes from, where our drugs come from. we have two of the biggest drugs in the history of the industry with dupixent and eylea. we don't buy them from somebody

else. our scientific officer and the team invent these. they come from our pipeline. we have proven we can do that. we have two mega block busters. ten drugs approved. 40 drugs in development. 40 drugs at the conference here this week we talked about ten of them addressing markets in maybe $200 billion. >> explain why people feel that you are after niche areas. >> i on't understand why people feel that. >> allergy they think is niche. >> that's silly. how many people have serious allergic diseases? there's a tremendous need. our first patient is a patient who is allergic to so many things that the only thing this person could eat is formula, chicken and potatoes. nothing else. imagine that existence. allergy is a very big problem.

it's a serious problem. people can die from allergic diseases. >> inflammation, talk about ecsima. if i showed you babies and after a few doses, we have seen the miraculous -- i use the word miraculous, because the effect on some people's eczema is miraculous. some people have what's called type two inflammation. it gets manifested in many different ways. some people, as eczema, some as

as asthma, some people as nasal polyps. the common thing is type two inflammation. our drug naturally, if it's able to block type two inflammation will work in a va rye a variety of items. >> i want to go back to eylea. you said, do it only once a month. this is now not even once a month. people feel that it no longer is an important drug. can you explain why those -- why don't you say why those narratives are incorrect. >> i think you have to understand that first of all, thanks to am gen. imitation is the best form of flattery. god bless them. we would rather spend our time

innovating. we bring forward -- they are working on yesterday's news, which is eylea. we are working on the next generation, eylea hd. they are chasing the future. we're trying to create the future. >> one thing -- do people realize you have a formative on? >> we have crossed a billion dollars. we re going after tens of billions of dollars. just yesterday, we announced the study. you might find this fascinating. we did a study in what's called squamous cell carcinoma where people who -- >> skin cancer. >> skin cancer. people have had surgery. the docs are afraid it would come back. >> it does come back. >> it does, unfortunately. it can be bad whether n it come. we showed a 68% reduction on the risk of coming back.

our competitor, keytruda did the same setting, they are nothing. their trial failed. i feel regeneron knows how to make and develop drugs for important conditions. this is an important condition. we will submit it to the fda shortly. >> people are concerned about in the current administration, president biden didn't want to be in the same room as ceos. how would you regard your relationship with president trump? >> well, i would say the pillar of that relationship might be that the drug that george invented, probably saved his life. >> that could be in a transactional presidency, that could play a role. >> perhaps. that's what we do. we try and save people's lives. we saved the president's life. >> what do you think happened to -- it's up to me to talk about the stock. how did the an alysts get

trapped? this is an opportunity for people to think long-term to buy. >> i think people have a hard time with regeneron that has 40 things in the pipeline, 40 things. it's hard to focus. they focus on something that's easy for them to look at. a quarterly number. we are looking out over years and decades and so forth. there's a little bit of n iceberg affect that people looked at something and they missed the picture. we are the company that brought you two of the biggest drugs in the history of the industry. our pipeline of 40 i think is going to bring you more of those. >> i'm glad you are taking a long-term view. our first guest, $5. i call that bankable. thank you. >> thank you. great to see you. >> when we return, master the markets one stock at a time.

the lightning round is up next. ♪♪ only servicenow connects every corner of your business, putting ai to work for people. pfft ... every corner? every corner, nick. ow! so kate in hr ... hey kate. can focus on people, not process. patty in it is using ai agents to deal with the small stuff, so she can work on the big stuff. and ai helps jim solve customer problems before they're problems. oh, so we all work better, together! my work here is done. excuse me, which way back?

sofi is helping me get my money right to achieve my ambitions. like a saving for a better swing. loosen that grip. with sofi, i earn more money on my money and pay no account fees. plus i'm investing in my game. sofi can help fund all your ambitions. (♪♪) no matter how ambitious. bank with sofi to score a higher apy and an epic welcome bonus. sofi. get your money right.

i would like to dedicate this to a staffer who is faster than lightning and just ran nearly 50 miles in a few days at disney world. it's alyssa the sherman-ator as i call it. it's the lightning round. are you ready?

let's start with tyrone in virginia. >> caller: i was looking at starbucks. i'm intrigued. taking it to the top. >> i will give you a two for. starbucks, i like. i think christine is doing a remarkable job. the stock is active. let's go to tom in arizona. >> caller: jim, i'm calling about a market darling in may. but it has tanked since. it does 8% dividend. the quarterly amount fluctuates. an lifrlts alysts are all over . >> i'm not a fan of ardmore shipping. i'm not a fan of commercial

cargo ships because they tend to be episodic. jerry in arizona. >> caller: good afternoon. i'm calling to ask you for your opinion. my stock has just been accused of falsifying and ernst & young quit. earnings have been delayed because of this. my question is, is smci super microcomputer a buy, sell or hold? >> i have strict rules on companies that have accounting issues. that is sell. it doesn't matter. i don't care. that's it. accounting irregularities make me sell. mark in new jersey. mark. why don't we go to sam? sam in pennsylvania. sam. >> caller: jim, how are you doing? let's go birds.

>> go eagles. >> caller: a company i discovered on my way into philadelphia. that's smc. >> well aware of it, the old food machinery company. i love philadelphia. i can only rate that a hold. i don't like the sector. i'm not there for that. i'm sorry. that, ladies and gentlemen is the conclusion of the lightning round. >> the lightning round is sponsored by charles schwab. coming up, could the drug distributors be an under the radar winner in the healthcare space? cramer is going one on one with cardinalhealth to see how it brings treatments from pharma companies to patients, next.

carl: believe me, when it comes to investing, you'll love carl's way. take a left here please. driver: but there's a... carl's way is the best way. client: is it? at schwab, how i choose to invest is up to me. driver: exactly! i can invest and trade on my own... client: yes, and let them manage some investments for me too. let's move on, shall we? no can do. client: i'll get out here. where are you going?? schwab. schwab! schwab. a modern approach to wealth management.

♪♪ ♪♪ ♪♪ ♪♪ ♪♪ ♪♪ at state street, we know everyone's trying to get somewhere. ♪♪ take the next step toward your future, by investing in the s&p 500 with spy. getting there starts here. appreciate it so much. thank you. doors are new beginnings. -surprise! -surprise! your dedicated fidelity advisor can help you open those doors. for you, mama. through personalized money management that can evolve with new chapters.

and they can proactively view your entire portfolio. with an eye on taxes and the impact of risk. so you can enjoy moments together. because doors were meant to be opened. doors lead us to new opportunities. your dedicated fidelity advisor... -surprise! -for you, mama. ...can help you open those doors. by proactively reviewing your entire portfolio. with an eye on taxes and risk. doors were meant to be opened.

gotta say, i love an industry that can take political heat without it doing too much damage to the stocks, to say nothing of the earnings. take the drug distributors. trump has bashed them. but they also save their customers a lot of money. take cardinal health. they announced their earnings for the fiscal year should come in at the high end of the previous guidance. doesn't hurt the stock is cheap. is that enough given the industry could have a target

payment on its back? we checked in with the ceo of cardinal health on the sidelines of the jp morgan healthcare conference. take a look. a lot of people think your company is just a middle man. you have reinvented this company. you are now a force to help community-based physicians. you are also -- you have done private label. this is not the old cardinal. >> we had some of those pieces for many, many years. you are right, we are leaning into investment on the wide end of the spectrum. when you think about where cardinal health participates, it's the beginning, middle and end. we work with every innovator, and we deliver through the infrastructure to the final customer, final providers. in some cases directly to the patient. in some cases, we are the provider. in some cases, the manufacturer. we are not just the middle. he would are throughout the spectrum of the business. >> why do you think people don't see that? >> i think they do more and

more. especially who matters most, our customers and patients, those that rely on us for the service. i think there's opportunities to tell the story more, more broadly to investors and the public. we are a b to b company. we are focused on making sure our customers' needs are taken care of. >> when i saw you last, you were talking about making acquisitions. they might change again. the face of the company. then you proceeded to do very big ones. it didn't hurt the balance sheet. >> right. consistent with our strategy. what we have done with specialty business, three of the four acquisitions that we have done more recently, is very much focussed on providing a broader capability for that specialty community physician. that physician has needs. they have received great service as relates to distribution and other contracting support. what we have done is augmented our capabilities to provide other data technology solutions like the pps analytics we acquired with the specialty network acquisition to provide full capability for helping those physicians manage the

clinical and communication needs with their patients. also more recently, big in oncology and gi is msos to help physicians manage the back office as well as the complex administrative things. >> the gi alliance, advanced diabetics support supply group, these are things i don't see otherwise. explain to people. these are what i call proprietary business, not commodity business. >> that's right. higher margin, very fast growing businesses. two very different acquisitions and two different swas paces. gi alliance, it's focused today on the gi space, gastroenterology. what we saw with that is a fantastic opportunity to expand beyond gi into other therapeutic areas. what we are doing with msos and specialty support is having two independent platforms. one for oncology. they have very special needs. the other one is in the other 60% of the marketplace.

that is gi, rheumatology, urology, neurology. there's a lot of opportunities for us to take that very strong start that gi alliance has built and bring it into those other therapeutic areas. >> talk about the back end. you are a technologist. you have used quietly artificial intelligence in a way that it made it so your customer service business is generating not the negativity everybody else. >> we are using it across the business. we don't talk about ai for ai sake. what does it do for the efficiency of the business? what does it do for our customers, for the providers? it is those outcomes that help the patients but creating value for that physician. also, of course, we participate in that as well. >> what people don't realize is you have a substantial -- pbm, a substantial business. you are -- optim rx. >> it was.

it's no longer a customer of ours. >> it didn't hurt you. >> that's right. we had a clear plan. >> lost the second largest customer. people have to realize, most companies would miss their quarter, miss their quarter. >> we had a strong plan to remediate that. it was $40 billion of revenue that was a cliff event at the beginning of the fiscal year. we had a strong plan in place. we got on it. we already had a lot of commercial momentum with other customers. our value proposition was stronger with other customers. it was a good customer, but low margin. the volume was volatile and more complex to support. what we have done is taken that time, attention and capacity and focussed on customers that value those services. in addition, we made other investments. >> one of the reasons why people hated cardinal, because if you lose your second largest customer, you cannot make the numbers. you made it up with better margin, including acquisition. you ran cardinal better. i think that's why this stock is

at a 52-week high. most, 52-week low. >> we execute cd on this business. even with that plan, we only had a 1% to 3% earning growth for the pharma segment of the last quarter, a fantastic first year. our long-term expectations for the business. this morning, we are at the high end of expectations for the year, which means that you would expect us to fake expectations above the 4% to 6%. that's in a year where we had that. we had headwinds related to lower covid vaccine. we manage through that. >> they have tripped up other companies. this is special. most of the companies here are trying to get people to look at their stock. your stock is glaring. it's at a 52-week high, not low. congratulate you, ceo of cardinal health, who lost the second largest customer and still beat the quarter and year. congratulations. >> thanks.

>> i learned so much from the ceos who joined us. tune in tomorrow for an action-packed lineup. including the mayor of san francisco. i would like to say there's always a bull market somewhere. i prop is i promise to find it right here for you on "mad money." i'm jim cramer. see you tomorrow. investment will face these sharks. if they hear a great idea, they'll invest their own money or fight each other for a deal. this is "shark tank." or fight each other for a deal. this is "shark tank." ♪♪ first into the shark tank is jonathan boos with an innovative product line for the well-dressed man. hi, everyone. my name is jonathan boos,